Clinical leadership Quark is a world leader in novel therapeutic RNAi with the largest clinical-stage siRNA pipeline and two candidates in pivotal Phase III studies, signaling strong near-term potential for partnerships or licensing deals in late-stage programs.

Global network A distributed clinical studies network, including a China JV (Kunshan Ribo-Quark) and a strategic partner in India (Biocon Limited), creates co-development and signaling opportunities for regional collaborations, trials, and market access strategies.

Delivery platform Quark’s tissue-targeted delivery across eye, kidney, ear, lung, skin, spinal cord, and brain suggests potential for co-development or outsourcing arrangements with CROs and biopharma seeking RNAi delivery capabilities or expansion into multi-tissue indications.

Financial runway With modest revenue and $61M in funding, Quark presents an opportunity for early-stage partnerships, strategic investments, or milestone-driven collaborations aligned with its ongoing Phase III programs and platform advantage.

Geographic focus Headquartered in California with R&D bases in Colorado and Israel and international partnerships, Quark is well-positioned for U.S. and international deals, including co-development, manufacturing alliances, and regional market-entry collaborations.